{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:36:42Z","timestamp":1760060202190,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T00:00:00Z","timestamp":1754784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This was a single-centre retrospective cohort study of patients diagnosed with glioblastoma (GB) at the Juravinski Cancer Centre (JCC). The charts of 528 patients diagnosed with GB at the JCC from an 8-year period from 1 January 2013, to 31 December 2020, were reviewed. The primary objective was to assess the incidence of venous thromboembolism (VTE) in newly diagnosed GB. The secondary objective was to identify patients at higher risk of developing VTE to understand who might benefit from prophylactic anticoagulation. Data on the following factors were collected: date of diagnosis, time to death or last follow-up, location and size of tumour, degree of resection, presence and location of weakness, performance status, body mass index, comorbidities (hypertension, diabetes, dyslipidemia, smoking history), baseline blood counts, and treatments administered. A total of 111 of the 528 patients (21%) were diagnosed with VTE. Most VTE (87%) occurred within 12 months of diagnosis. A previous cancer diagnosis and recurrence or disease progression were the only factors identified as predictive of a higher risk for developing thrombosis. Newly diagnosed patients with GB have been shown to have a significant risk of developing VTE. Consideration should be given for prophylactic anticoagulation at the time of diagnosis.<\/jats:p>","DOI":"10.3390\/curroncol32080449","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T09:04:53Z","timestamp":1754903093000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Venous Thromboembolism in Newly Diagnosed Glioblastoma and Associated Risk Factors: A Retrospective Chart Review"],"prefix":"10.3390","volume":"32","author":[{"given":"Duaa","family":"Binjabal","sequence":"first","affiliation":[{"name":"Department of Oncology, International Medical Centre, Jeddah 23214, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser","family":"Al Majarafi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-0882","authenticated-orcid":false,"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2888-4146","authenticated-orcid":false,"given":"Hal","family":"Hirte","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence based review","volume":"89","author":"Marras","year":"2000","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2005.04.6656","article-title":"Management of venous thromboembolism in patients with primary and metastatic brain tumors","volume":"24","author":"Gerber","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","article-title":"Recurrent venous thromboembolism in glioblastoma","volume":"137","author":"Edwin","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","article-title":"Epidemiology of venous thromboembolism in 9489 patients with malignant glioma","volume":"106","author":"Semrad","year":"2007","journal-title":"J. Neurosurg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0959-8049(97)00167-6","article-title":"Incidence and risk of thromboembolism during treatment of high-grade gliomas: A prospective study","volume":"33","author":"Brandes","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/blood.2022017858","article-title":"Determining venous thromboembolism risk in patients with adult-type diffuse glioma","volume":"141","author":"Burdett","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0039-1688493","article-title":"Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges","volume":"45","author":"Riedl","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.thromres.2015.10.043","article-title":"Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry","volume":"136","author":"Portillo","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_10","first-page":"e2678","article-title":"Risk of venous thromboembolism in glioblastoma patients","volume":"10","author":"Lim","year":"2018","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.wneu.2017.12.139","article-title":"High incidence of deep vein thrombosis in the perioperative period of neurosurgical patients","volume":"112","author":"Natsumeda","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/neuonc\/noad059","article-title":"Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review","volume":"25","author":"Jo","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_14","first-page":"e1063","article-title":"Risk of Venous Thromboembolism in Grade II\u2013IV Gliomas as a Function of Molecular Subtype","volume":"96","author":"Diaz","year":"2021","journal-title":"Neurol"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2022.08.029","article-title":"Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis","volume":"219","author":"Low","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1215\/15228517-2006-035","article-title":"Venous thromboembolism and survival in patients with high-grade glioma","volume":"9","author":"Simanek","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11060-016-2259-x","article-title":"Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: A meta-analysis","volume":"130","author":"Alshehri","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: A randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"Perry","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1055\/s-0040-1712143","article-title":"Assessing full benefit of rivaroxaban prophylaxis in high-risk ambulatory patients with cancer: Thromboembolic events in the randomized CASSINI Trial","volume":"4","author":"Khorana","year":"2020","journal-title":"TH Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10143-021-01539-9","article-title":"Direct oral anticoagulants versus low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma","volume":"45","author":"Dubinski","year":"2022","journal-title":"Neurosurg. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11239-021-02537-w","article-title":"Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma","volume":"53","author":"Thomas","year":"2022","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:27Z","timestamp":1760034447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,10]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["curroncol32080449"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32080449","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,8,10]]}}}